Novo Nordisk Archives - Medical Design Sourcing

Novo Nordisk acquires all shares of drug delivery device maker Biocorp

The Mallya smart insulin pen device pairs with the Novo Nordisk FlexTouch pen. [Image from Biocorp]Novo Nordisk today officially acquired 100% of the shares of Biocorp, the France-based drug delivery device maker’s CEO announced.

Biocorp designs, develops and manufactures drug delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors.

The Mallya smart sensor attaches directly to insulin pen injectors to make them connected devices. It automatically collects and records key treatment information, then transmits the information to a dedicated digital application. That data includes selected insulin units, date and time of injection. The FDA cleared Mallya in December 2022.

Get the full story at our sister site, Drug Delivery Business News.

Ypsomed concludes autoinjector supply deal with Novo Nordisk

The YpsoMate 1mL autoinjector. [Image from Ypsomed]Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors.

Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its manufacturing capacities over the coming years.

Novo Nordisk expects to contribute a significant part of the investment for additional production infrastructure. The companies expect availability of a significant capacity of autoinjectors for Novo Nordisk “in the course of 2025.”

Get the full story at our sister site, Drug Delivery Business News.

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a range of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.<…

Novo Nordisk looks to acquire a majority stake in BioCorp for $164.5M

The Mallya smart insulin pen device pairs with the Novo Nordisk FlexTouch pen. [Image from Biocorp]Novo Nordisk announced today that it entered into exclusive negotiations for a controlling stake in drug delivery device maker Biocorp.

France-based Biocorp specializes in the design, development and manufacturing of delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors.

Mallya, a smart sensor, attaches directly to insulin pen injectors to make them connected devices. It automatically collects and records key treatment information and transmits it to a dedicated digital application. That data includes selected insulin units, date and time of injection. The FDA cleared Mallya in December 2022.

Novo Nordisk and Biocorp have collaborated on Mallya’s development and commercialization since 2021. It pairs with the FlexTouch pen for people with diabetes. The two companies expanded their pa…

Novo Nordisk to lower pre-filled insulin device prices by up to 75%

Novo Nordisk announced today that it plans to lower U.S. prices of several insulin products by up to 75% for those with type 1 and type 2 diabetes.

Products include pre-filled insulin pens and vials of basal, bolus and pre-mix insulins. These specifically include Levemir, Novolin, NovoLog and NovoLog Mix 70/30. Novo Nordisk also plans to reduce the price of unbranded biologics to match the lowered price of each respective branded insulin.

The price cut comes two weeks after Eli Lilly announced plans to cap out-of-pocket insulin costs at $35 with 70% price cuts. Novo Nordisk’s changes go into effect on Jan. 1, 2024.

Get the full story at our sister site, Drug Delivery Business News.

The year ahead in diabetes care: what to expect in 2023

[Image courtesy of Walmart] After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023.

Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more.

You can read all about the biggest diabetes stories of 2022 here.

As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.

CMS decision could benefit CGMs

In October, The Centers for Medicare and Medicaid Services (CMS) published a new local coverage determination (LCD). That LCD modified coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.

Analysts suggested at the time that the decision marked a win for …

Amalgam Rx, Novo Nordisk expand partnership on connected insulin delivery devices

[Image courtesy of Amalgam Rx/Novo Nordisk]Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check.

Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin.

The two companies partnered to incorporate and integrate connected insulin delivery devices, continuous glucose monitors and electronic health records. Novo Nordisk also intends to make an equity investment in Amalgam.

Get the full story at our sister site, Drug Delivery Business News.

Abbott FreeStyle LibreLink app now pairs with Novo Nordisk insulin pens in UK

The NovoPen Echo smart insulin pen. [Image from Novo Nordisk]Novo Nordisk (NYSE:NVO) announced that users of the Abbott (NYSE:ABT) FreeStyle LibreLink app can connect to its smart insulin pens.

People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. Users of the Abbott FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology can see a range of information related to their diabetes. This includes dose timing and the amount of insulin taken, plus how those metrics impact their individual glucose patterns.

Get the full story at our sister site, Drug Delivery Business News.

WHO delivers insulin pens to Ukraine hospitals with support from Novo Nordisk

[Image from WHO]The World Health Organization (WHO) announced that it delivered more than 26 metric tonnes of insulin pens to Ukraine.

WHO distributed approximately 57,320 pounds of insulin pens (more than 370,000 total pens) to hospitals throughout Ukraine. It represents part of an effort to help those with diabetes in the country during the ongoing humanitarian crisis.

Get the full story at our sister site, Drug Delivery Business News.

10 leading pharma executives you need to know

Pfizer CEO Dr. Albert Bourla [Image courtesy of Pfizer/Business Roundtable]Given the complexity of the pharmaceutical business, it can be challenging to gauge the performance of any chief executive in the space.

That said, CEOs’ annualized return over tenure as CEO over their term can hint at performance. In addition, rating sites like Glassdoor also indicate CEOs’ popularity.

Here, we parsed a range of metrics, including CEOs’ approval ratings, their ability to navigate the pandemic and their firms’ stock performance over time, to identify ten leading pharma executives.

Get the full story from our sister site, Drug Discovery & Development.

Novo Nordisk completes acquisition of Dicerna Pharmaceuticals

Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed.

Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. ET on Dec. 24, 2021.

Get the full story at our sister site, Drug Delivery Business News.

Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires

Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired.

The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on Dec. 24, 2021.

Get the full story at our sister site, Drug Delivery Business News.